300 related articles for article (PubMed ID: 34353323)
21. Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study.
Russell C; Ali F; Nafeh F; Rehm J; LeBlanc S; Elton-Marshall T
J Subst Abuse Treat; 2021 Oct; 129():108374. PubMed ID: 34080545
[TBL] [Abstract][Full Text] [Related]
22. Peer worker involvement in low-threshold supervised consumption facilities in the context of an overdose epidemic in Vancouver, Canada.
Kennedy MC; Boyd J; Mayer S; Collins A; Kerr T; McNeil R
Soc Sci Med; 2019 Mar; 225():60-68. PubMed ID: 30798157
[TBL] [Abstract][Full Text] [Related]
23. A qualitative examination of substance use service needs among people who use drugs (PWUD) with treatment and service experience in Ontario, Canada.
Russell C; Ali F; Nafeh F; LeBlanc S; Imtiaz S; Elton-Marshall T; Rehm J
BMC Public Health; 2021 Nov; 21(1):2021. PubMed ID: 34742267
[TBL] [Abstract][Full Text] [Related]
24. Using drugs in un/safe spaces: Impact of perceived illegality on an underground supervised injecting facility in the United States.
Davidson PJ; Lopez AM; Kral AH
Int J Drug Policy; 2018 Mar; 53():37-44. PubMed ID: 29278831
[TBL] [Abstract][Full Text] [Related]
25. Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives.
Austin EJ; Corcorran MA; Briggs ES; Frost MC; Behrends CN; Juarez AM; Frank ND; Healy E; Prohaska SM; LaKosky PA; Kapadia SN; Perlman DC; Schackman BR; Jarlais DCD; Williams EC; Glick SN
Int J Drug Policy; 2022 Nov; 109():103825. PubMed ID: 35977459
[TBL] [Abstract][Full Text] [Related]
26. Substance Use Stigma and Community Drug Checking: A Qualitative Study Examining Barriers and Possible Responses.
Davis S; Wallace B; Van Roode T; Hore D
Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36498052
[TBL] [Abstract][Full Text] [Related]
27. Feasibility and acceptability of inserts promoting virtual overdose monitoring services (VOMS) in naloxone kits: a qualitative study.
Safi F; Rioux W; Rider N; Fornssler B; Jones S; Ghosh SM
Harm Reduct J; 2023 May; 20(1):64. PubMed ID: 37158926
[TBL] [Abstract][Full Text] [Related]
28. The impact of COVID-19 on access to harm reduction, substance use treatment and recovery services in Scotland: a qualitative study.
Schofield J; Dumbrell J; Matheson C; Parkes T; Bancroft A
BMC Public Health; 2022 Mar; 22(1):500. PubMed ID: 35287630
[TBL] [Abstract][Full Text] [Related]
29. Moving towards a continuum of safer supply options for people who use drugs: A qualitative study exploring national perspectives on safer supply among professional stakeholders in Canada.
Foreman-Mackey A; Pauly B; Ivsins A; Urbanoski K; Mansoor M; Bardwell G
Subst Abuse Treat Prev Policy; 2022 Oct; 17(1):66. PubMed ID: 36209227
[TBL] [Abstract][Full Text] [Related]
30. Mobile supervised consumption services in Rural British Columbia: lessons learned.
Mema SC; Frosst G; Bridgeman J; Drake H; Dolman C; Lappalainen L; Corneil T
Harm Reduct J; 2019 Jan; 16(1):4. PubMed ID: 30634986
[TBL] [Abstract][Full Text] [Related]
31. Why are some people who have received overdose education and naloxone reticent to call Emergency Medical Services in the event of overdose?
Koester S; Mueller SR; Raville L; Langegger S; Binswanger IA
Int J Drug Policy; 2017 Oct; 48():115-124. PubMed ID: 28734745
[TBL] [Abstract][Full Text] [Related]
32. 'Why would we not want to keep everybody safe?' The views of family members of people who use drugs on the implementation of drug consumption rooms in Scotland.
Parkes T; Price T; Foster R; Trayner KMA; Sumnall HR; Livingston W; Perkins A; Cairns B; Dumbrell J; Nicholls J
Harm Reduct J; 2022 Aug; 19(1):99. PubMed ID: 36038919
[TBL] [Abstract][Full Text] [Related]
33. Operating an overdose prevention site within a temporary emergency shelter during the COVID-19 pandemic.
Galarneau LR; Speed K; Taylor M; Hyshka E
Can J Public Health; 2023 Oct; 114(5):787-795. PubMed ID: 37462841
[TBL] [Abstract][Full Text] [Related]
34. Substance use care innovations during COVID-19: barriers and facilitators to the provision of safer supply at a toronto COVID-19 isolation and recovery site.
Kolla G; Tarannum CN; Fajber K; Worku F; Norris K; Long C; Fagundes R; Rucchetto A; Hannan E; Kikot R; Klaiman M; Firestone M; Bayoumi A; Laurence G; Hayman K
Harm Reduct J; 2024 Jan; 21(1):17. PubMed ID: 38243267
[TBL] [Abstract][Full Text] [Related]
35. Investigating uses of peer-operated Virtual Overdose Monitoring Services (VOMS) beyond overdose response: a qualitative study.
Rider N; Safi F; Marshall T; Jones S; Seo B; Viste D; Taplay PE; Rioux W; Ghosh SM
Am J Drug Alcohol Abuse; 2023 Nov; 49(6):809-817. PubMed ID: 37956211
[No Abstract] [Full Text] [Related]
36. Hoots and harm reduction: a qualitative study identifying gaps in overdose prevention among women who smoke drugs.
Bardwell G; Austin T; Maher L; Boyd J
Harm Reduct J; 2021 Mar; 18(1):29. PubMed ID: 33678163
[TBL] [Abstract][Full Text] [Related]
37. "If I had them, I would use them every time": Perspectives on fentanyl test strip use from people who use drugs.
Reed MK; Salcedo VJ; Guth A; Rising KL
J Subst Abuse Treat; 2022 Sep; 140():108790. PubMed ID: 35577663
[TBL] [Abstract][Full Text] [Related]
38. The impact of the COVID-19 pandemic on illicit drug supply, drug-related behaviour of people who use drugs and provision of drug related services in Georgia: results of a mixed methods prospective cohort study.
Otiashvili D; Mgebrishvili T; Beselia A; Vardanashvili I; Dumchev K; Kiriazova T; Kirtadze I
Harm Reduct J; 2022 Mar; 19(1):25. PubMed ID: 35264181
[TBL] [Abstract][Full Text] [Related]
39. Critical studies of harm reduction: Overdose response in uncertain political times.
Watson TM; Kolla G; van der Meulen E; Dodd Z
Int J Drug Policy; 2020 Feb; 76():102615. PubMed ID: 31837567
[TBL] [Abstract][Full Text] [Related]
40. Awareness and knowledge of the Good Samaritan Drug Overdose Act among people at risk of witnessing an overdose in British Columbia, Canada: a multi-methods cross sectional study.
Ackermann E; Kievit B; Xavier J; Barbic S; Ferguson M; Greer A; Loyal J; Mamdani Z; Palis H; Pauly B; Slaunwhite A; Buxton JA
Subst Abuse Treat Prev Policy; 2022 May; 17(1):42. PubMed ID: 35614474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
